AstraZeneca Plunges After New Heart Disease Drug Fails Trial
AstraZeneca’s shares fell as much as 10.6% in London, which is its largest intraday plummet since 2017, per Bloomberg. The post AstraZeneca Plunges After New Heart Disease Drug Fails Trial appeared…
Read the full articleYou might also wanna read
AstraZeneca loses £20bn in value after major heart drug trial setback
AstraZeneca suffered one of its biggest market setbacks in years after disappointing trial results for a key heart disease drug wiped more t
Astrazeneca shares fall 9% after Wainua heart drug fails Phase 3 trial
Svensk-britiske Astrazeneca er havnet i modvind på børsen torsdag oven på et sæt skuffende resultater fra et fase 3-studie med hjertemidlet
finans.dk·23h ago
AstraZeneca sees stock market value slump by more than £20bn after drug setback
The FTSE 100 firm found the Wainua drug failed to meet a goal to reduce deaths related to heart disease.
AstraZeneca sees stock market value slump by more than £20bn after drug setback
The FTSE 100 firm found the Wainua drug failed to meet a goal to reduce deaths related to heart disease.
STAT+: AstraZeneca, Ionis report major trial failure with heart disease drug
AstraZeneca and Ionis reported a notable trial failure Thursday in a heart disease that's become an increasingly competitive market for drug
Thursday’s Stock Market Winners and Losers: Alnylam Pharmaceuticals (ALNY) Jumps 18% as AstraZeneca (AZN) Plunges
Alnylam Pharmaceuticals (ALNY) surges 18% in premarket trading while AstraZeneca (AZN) drops 9% on failed trial. See Thursday's biggest stoc
Comments
Sign in to join the conversation.
No comments yet. Be the first.